Accelerating innovation and ensuring the thoughtful withdrawal of lifeline medicines for people living with diabetes in Asia.

IF 3.2 3区医学

Journal of Diabetes Investigation Pub Date : 2025-05-20 DOI:10.1111/jdi.70063

Yutaka Seino, Daisuke Yabe, Sung Hee Choi, Chih-Cheng Hsu, Chien-Ning Huang, Altaisaikhan Khasag, Kathryn Tan, Kohjiro Ueki, Yuichiro Yamada, Zhanay A Akanov, Takashi Kadowaki

引用次数: 0

Abstract

Coordinated regional action is urgently needed to safeguard insulin access in Asia amid global product realignment. This editorial emphasizes the ethical imperative and policy frameworks required to balance innovation with equitable, uninterrupted diabetes care.

查看原文本刊更多论文

加快创新，确保亚洲糖尿病患者周全地停用生命线药物。

在全球产品调整的背景下，迫切需要采取协调一致的区域行动来保障亚洲的胰岛素可及性。这篇社论强调在创新与公平、不间断的糖尿病护理之间取得平衡所需的伦理责任和政策框架。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Diabetes Investigation Medicine-Internal Medicine

自引率

9.40%

发文量

218

期刊介绍： Journal of Diabetes Investigation is your core diabetes journal from Asia; the official journal of the Asian Association for the Study of Diabetes (AASD). The journal publishes original research, country reports, commentaries, reviews, mini-reviews, case reports, letters, as well as editorials and news. Embracing clinical and experimental research in diabetes and related areas, the Journal of Diabetes Investigation includes aspects of prevention, treatment, as well as molecular aspects and pathophysiology. Translational research focused on the exchange of ideas between clinicians and researchers is also welcome. Journal of Diabetes Investigation is indexed by Science Citation Index Expanded (SCIE).